Your search for major depressive disorder returned 67 results

Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.

Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.

The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.

Acceptability of a passive smartphone-based ecological momentary assessment (EMA) app is relatively low among individuals with schizophrenia spectrum disorders.

This was a study protocol for a phase II pilot feasibility study that will assess the feasibility of ketamine for depression in patients with advanced life-limiting illnesses.

Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.

Patients with depression can live with symptoms for a long period of time before finding an option that works. One possibility for patients who are unable to find relief through pharmacology is transcranial magnetic stimulation. An expert offers his view on this form of treatment.

NP expert discusses screening and treatments for anxiety in children and adolescents in the primary care setting.

Suicidal ideation, plan, and attempt in young U.S. adults increased from 2008-2009 to 2018-2019 after controlling for MDE, cannabis use, and CUD.

Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.

Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

Researchers compared how patients experiencing a major depressive episode and control participants perceived contrast patterns.

For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

Researchers from Dalhousie University in Canada searched publication databases through September of 2020 for articles on ADHD, attention deficit disorder, bipolar disorder, and affective psychosis.

While treatment for mood stabilization in bipolar disorder is most commonly lithium, all patients do not respond to such treatment. The authors of this study investigated what causes lithium resistance.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

Researchers performed a double-blind randomized study to investigate the efficacy of tDCS as an augmentation strategy to sertraline in the treatment of vascular depression.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.

Depression has been linked to elevated markers of inflammation, and aspirin, a nonsteroid, anti-inflammatory medication, can irreversibly inhibit cyclooxygenase-1 and 2.